- $137.44m
- $193.98m
- $70.99m
- 40
- 44
- 42
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -32.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 34.63 | 49.12 | 74.65 | 76.28 | 70.99 | 91.38 | 129.93 | 58.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
Directors
- Joseph Scodari NEC (68)
- Ramy Mahmoud PRE (56)
- Peter Miller CEO (59)
- Keith Goldan CFO (50)
- Victor Clavelli OTH (48)
- Michael Marino SEC (45)
- Eric Bednarski DRC
- Kyle Dempsey DRC
- Wilhelmus Groenhuysen IND (63)
- Sandra Helton IND (71)
- Tomas Heyman IND (65)
- Catherine Owen IND (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 26th, 2010
- Public Since
- October 13th, 2017
- No. of Shareholders
- 18
- No. of Employees
- 132
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 112,651,740
- Address
- 1020 Stony Hill Rd Ste 300, YARDLEY, 19067-5539
- Web
- https://www.optinose.com/
- Phone
- +1 2673643500
- Contact
- Jonathan Neely
- Auditors
- Ernst & Young LLP
Upcoming Events for OPTN
OptiNose Inc Annual Shareholders Meeting
Q2 2024 OptiNose Inc Earnings Release
Similar to OPTN
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the OptiNose share price?
As of Today at 19:16 UTC, shares in OptiNose are trading at $1.22. This share price information is delayed by 15 minutes.
How has the OptiNose share price performed this year?
Shares in OptiNose last closed at $1.22 and the price had moved by -37.11% over the past 365 days. In terms of relative price strength the OptiNose share price has underperformed the S&P500 Index by -49.21% over the past year.
What are the analyst and broker recommendations for OptiNose?
The overall consensus recommendation for OptiNose is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the OptiNose dividend yield?
OptiNose does not currently pay a dividend.
Does OptiNose pay a dividend?
OptiNose does not currently pay a dividend.
When does OptiNose next pay dividends?
OptiNose does not currently pay a dividend.
How do I buy OptiNose shares?
To buy shares in OptiNose you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of OptiNose?
As of the previous close price of $1.22, shares in OptiNose had a market capitalisation of $137.44m.
Where are OptiNose shares listed?
Here are the trading details for OptiNose:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OPTN
What kind of share is OptiNose?
Based on an overall assessment of its quality, value and momentum OptiNose is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a OptiNose share price forecast for 2024?
The analyst consensus target price for shares in OptiNose is $3.75. That is 207.38% above the last closing price of $1.22.
Analysts covering OptiNose currently have a consensus Earnings Per Share (EPS) forecast of -$0.26 for the next financial year.
What is the trend in the OptiNose share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OptiNose. Over the past six months, its share price has underperformed the S&P500 Index by -16.01%.
As of the last closing price of $1.22, shares in OptiNose were trading -5.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the OptiNose PE Ratio?
The OptiNose PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of OptiNose?
OptiNose's management team is headed by:
- Joseph Scodari - NEC
- Ramy Mahmoud - PRE
- Peter Miller - CEO
- Keith Goldan - CFO
- Victor Clavelli - OTH
- Michael Marino - SEC
- Eric Bednarski - DRC
- Kyle Dempsey - DRC
- Wilhelmus Groenhuysen - IND
- Sandra Helton - IND
- Tomas Heyman - IND
- Catherine Owen - IND